Test Catalog

Test Id : HSCRP

C-Reactive Protein, High Sensitivity, Serum

Useful For
Suggests clinical disorders or settings where the test may be helpful

Assessment of risk of developing myocardial infarction in patients presenting with acute coronary syndromes

 

Assessment of risk of developing cardiovascular disease or ischemic events in individuals who do not manifest disease at present

Method Name
A short description of the method used to perform the test

Immunoturbidimetry

NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test

C-Reactive Protein, High Sens, S

Aliases
Lists additional common names for a test, as an aid in searching

C Reactive Protein (CRP), Cardiac

C Reactive Protein, High Sensitivity

C-Reactive Prot, High Sens, Serum

C-Reactive Protein (CRP)

C-Reactive Protein, Cardio

C-Reactive Protein, Sensitive

Cardio C-Reactive Protein

CRP Cardiac

CRP, High Sensitivity

CRP, Highly Sensitive, (hs-CRP), Serum

CRP, Ultra-Sensitive, Serum

High-Sensitivity C-Reactive Protein (hs-CRP)

Protein, C-Reactive

Sensitive C-Reactive Protein

Ultra-Sensitive C-Reactive Protein (CRP)

Specimen Type
Describes the specimen type validated for testing

Serum

Ordering Guidance

This assay should be used to assess risk of cardiovascular disease or events.

 

To monitor or assess other inflammatory disorders, order CRP / C-Reactive Protein (CRP), Serum.

Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing

Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL

Collection Instructions: Centrifuge and aliquot serum into a plastic vial.

Forms

If not ordering electronically, complete, print, and send a Cardiovascular Test Request Form (T724) with the specimen.

Specimen Minimum Volume
Defines the amount of sample necessary to provide a clinically relevant result as determined by the testing laboratory. The minimum volume is sufficient for one attempt at testing.

0.2 mL

Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected

Gross hemolysis Reject
Gross lipemia Reject
Gross icterus Reject

Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 7 days
Frozen 30 days

Useful For
Suggests clinical disorders or settings where the test may be helpful

Assessment of risk of developing myocardial infarction in patients presenting with acute coronary syndromes

 

Assessment of risk of developing cardiovascular disease or ischemic events in individuals who do not manifest disease at present

Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

C-reactive protein (CRP) is a biomarker of inflammation. Serum CRP concentrations increase rapidly and dramatically (100-fold or more) in response to tissue injury or inflammation. High-sensitivity CRP (hs-CRP) is more precise than standard CRP when measuring baseline (ie, normal) concentrations and enables a measure of chronic inflammation.

 

Atherosclerosis is an inflammatory disease and hs-CRP has been endorsed by multiple guidelines as a biomarker of atherosclerotic cardiovascular disease risk.(1-3)

 

A large prospective clinical trial demonstrated significantly less cardiovascular risk for patients with hs-CRP less than 2.0 mg/L.(1) More aggressive treatment strategies may be warranted in patients with hs-CRP of 2.0 mg/L or higher.

Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

> or =18 years: <2.0 mg/L

Reference values have not been established for patients who are younger than 18 years.

Interpretation
Provides information to assist in interpretation of the test results

Values greater than 2.0 mg/L suggest an increased likelihood of developing cardiovascular disease or ischemic events.

Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

This test is recommended for cardiovascular risk assessment only.

 

C-reactive protein (CRP) is an acute-phase reactant and has high intra-individual variability. Therefore, a single test for high-sensitivity CRP (hs-CRP) may not reflect an individual patient's basal hs-CRP level. Repeat measurement may be required to firmly establish an individual's basal hs-CRP concentration. The lowest of the measurements should be used as the predictive value.

 

Because CRP is an acute-phase reactant, measurements in apparently healthy individuals may not truly reflect the basal level if inflammation is present.

 

This hs-CRP assay should be used to assess risk of cardiovascular disease or events. A different CRP test (CRP / C-Reactive Protein [CRP], Serum) should be used to monitor or assess other inflammatory disorders.

 

Significantly decreased CRP values may be obtained from samples taken from patients who have been treated with carboxypenicillins.(4)

 

No significant interference is seen from rheumatoid factors up to a concentration of 200 IU/mL.

Clinical Reference
Recommendations for in-depth reading of a clinical nature

1. European Association for Cardiovascular Prevention and Rehabilitation, Reiner Z, Catapano AL, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769-1818

2. Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. Circulation. 2014;129:S49-S73

3. Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary. J Clin Lipidol. 2014;8:473-488

4. Cardiac C-Reactive Protein (Latex) High Sensitive. V 12.0. Package insert: Roche Diagnostics; 03/2019

5. Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL-cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373:1175-1182

6. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2019;140:563-595

7. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107(3):499-511. doi:10.1161/01.cir.0000052939.59093.45

Method Description
Describes how the test is performed and provides a method-specific reference

This is a particle-enhanced immunoturbidimetric assay. Human C-reactive protein (CRP) agglutinates with latex particles coated with monoclonal anti-CRP antibodies. The precipitate is determined turbidimetrically.(Package insert: Cardiac C-Reactive Protein (Latex) High Sensitive. Roche Diagnostics; V15.0, 04/2024)

PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information

No

Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.

Monday through Saturday

Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.

Same day/1 to 2 days

Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded

7 days

Performing Laboratory Location
Indicates the location of the laboratory that performs the test

Rochester

Fees
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.

  • Authorized users can sign in to Test Prices for detailed fee information.
  • Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
  • Prospective clients should contact their account representative. For assistance, contact Customer Service.

Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.

This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.

CPT codes are provided by the performing laboratory.

86141

LOINC® Information
Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the order and results codes of this test. LOINC values are provided by the performing laboratory.

Test Id Test Order Name Order LOINC Value
HSCRP C-Reactive Protein, High Sens, S 30522-7
Result Id Test Result Name Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
HSCRP C-Reactive Protein, High Sens, S 30522-7

Test Setup Resources

Setup Files
Test setup information contains test file definition details to support order and result interfacing between Mayo Clinic Laboratories and your Laboratory Information System.

Excel | Pdf

Sample Reports
Normal and Abnormal sample reports are provided as references for report appearance.

Normal Reports | Abnormal Reports

SI Sample Reports
International System (SI) of Unit reports are provided for a limited number of tests. These reports are intended for international account use and are only available through MayoLINK accounts that have been defined to receive them.

SI Normal Reports | SI Abnormal Reports